We are live on ! Find out more
BG

Bellevue Group Portfolio holdings

AUM $4.2B
1-Year Est. Return 54.85%
This Fund
S&P 500
This Quarter Est. Return
+4.25%
1 Year Est. Return
+54.85%
3 Year Est. Return
+140.3%
5 Year Est. Return
+171.01%
10 Year Est. Return
+915.55%
AUM
$1.01B
AUM Growth
+$52.2M
Cap. Flow
+$30.7M
Cap. Flow %
3.04%
Top 10 Hldgs %
32.72%
Holding
140
New
6
Increased
28
Reduced
47
Closed
15

Top Buys

Rank Stock Value
1
TDOC icon
Teladoc Health
TDOC
+$17.7M
2
HUM icon
Humana
HUM
+$13.6M
3
KTWO
K2M Group Holdings, Inc
KTWO
+$13.2M
4
FIT
Fitbit, Inc. Class A common stock
FIT
+$12.2M
5
ESPR
Esperion Therapeutics
ESPR
+$12.1M

Top Sells

Rank Stock Value
1
LLY icon
Eli Lilly
LLY
+$20.4M
2
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$11.6M
3
TEVA icon
Teva Pharmaceuticals
TEVA
+$11.4M
4
THC icon
Tenet Healthcare
THC
+$9.34M
5
ONC
BeOne Medicines Ltd
ONC
+$8.53M

Sector Composition

Rank Sector Weight
1 Healthcare 95.24%
2 Industrials 0.39%
3 Financials 0.15%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CAH icon
101
Cardinal Health
CAH
$53.1B
$1.25M 0.12%
20,000
– –
AKCA
102
DELISTED
Akcea Therapeutics Inc
AKCA
$1.25M 0.12%
+48,799
New +$1.05M
RDUS
103
DELISTED
Radius Health, Inc.
RDUS
$1.2M 0.12%
33,300
-500
-1% -$18.1K
PRTA icon
104
Prothena Corp
PRTA
$451M
$1.13M 0.11%
30,850
-500
-2% -$18.2K
EXEL icon
105
Exelixis
EXEL
$14.2B
$1.1M 0.11%
49,800
-800
-2% -$22.1K
PFE icon
106
Pfizer
PFE
$142B
$1.04M 0.1%
30,777
– –
CLVS
107
DELISTED
Clovis Oncology, Inc.
CLVS
$937K 0.09%
17,750
-250
-1% -$14.6K
NVRO
108
DELISTED
NEVRO CORP.
NVRO
$927K 0.09%
10,700
– –
GKOS icon
109
Glaukos
GKOS
$9.18B
$925K 0.09%
30,000
– –
HMSY
110
DELISTED
HMS Holdings Corp.
HMSY
$901K 0.09%
53,500
– –
OMCL icon
111
Omnicell
OMCL
$2.08B
$868K 0.09%
20,000
– –
VAR
112
DELISTED
Varian Medical Systems, Inc.
VAR
$859K 0.09%
7,000
– –
ACAD icon
113
Acadia Pharmaceuticals
ACAD
$4.34B
$776K 0.08%
34,550
-500
-1% -$13.8K
COTV
114
DELISTED
Cotiviti Holdings, Inc.
COTV
$748K 0.07%
21,708
– –
MRK icon
115
Merck
MRK
$312B
$681K 0.07%
13,100
-15,720
-55% -$849K
MDCO
116
DELISTED
Medicines Co
MDCO
$580K 0.06%
17,600
-250
-1% -$7.81K
GWPH
117
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
$549K 0.05%
4,875
-75
-2% -$9.43K
CVS icon
118
CVS Health
CVS
$137B
$547K 0.05%
8,800
– –
SGRY icon
119
Surgery Partners
SGRY
$2.09B
$532K 0.05%
31,000
– –
QTNT
120
DELISTED
Quotient Limited Ordinary Shares
QTNT
$518K 0.05%
2,750
– –
AAC
121
DELISTED
AAC Holdings
AAC
$502K 0.05%
43,700
-1,300
-3% -$12.8K
ENDP
122
DELISTED
Endo International plc
ENDP
$369K 0.04%
62,200
-1,000
-2% -$6.99K
MYGN icon
123
Myriad Genetics
MYGN
$558M
$349K 0.03%
11,800
-200
-2% -$6.77K
CYTO
124
DELISTED
Altamira Therapeutics Ltd
CYTO
$347K 0.03%
27
– –
ABBV icon
125
AbbVie
ABBV
$450B
– –
-19,500
Closed -$1.89M
2 3 4
5
6

Similar funds

WSFS
Wilmington Savings Fund Society Wilmington, Delaware $4.2B AUM 18.37% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $4.22B AUM 21.28% 1-Year Est. Return
HIP
HUB Investment Partners Austin, Texas $4.18B AUM 24.76% 1-Year Est. Return
DT
DV Trading Chicago, Illinois $4.22B AUM
ATPW
Ashton Thomas Private Wealth Scottsdale, Arizona $4.23B AUM 20.9% 1-Year Est. Return
BT
Banque Transatlantique Paris, France $4.17B AUM 28.5% 1-Year Est. Return
NCM
Nearwater Capital Markets Dublin 4, Dublin, Ireland $4.24B AUM 66.03% 1-Year Est. Return
MSU
Mizuho Securities USA New York $4.24B AUM 23.1% 1-Year Est. Return

Bellevue Group's Q1 2018 Portfolio in Review

As of Q1 2018, Bellevue Group held 140 positions worth $1.01B, up 5.4% from $957M the previous quarter. Its ten largest holdings account for 33% of the portfolio.

Bellevue Group deployed $30.7M of net new capital in Q1 2018, opening 6 new positions and adding to 28 existing holdings. Its largest new stake was K2M Group Holdings, Inc: 667,941 shares worth $12.7M.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, down from 96% a quarter earlier, followed by Industrials and Financials.

On the sell side, the largest reduction was Teva Pharmaceuticals, an estimated $11.4M trimmed.

  • Bellevue Group's largest Q1 2018 buy was K2M Group Holdings, Inc: 667,941 shares worth $12.7M.
  • Bellevue Group added most to Teladoc Health in Q1 2018, an estimated $17.7M increase.
  • Bellevue Group's biggest Q1 2018 reduction was Teva Pharmaceuticals, cutting an estimated $11.4M.
  • Bellevue Group fully exited Eli Lilly in Q1 2018, selling an estimated $20.4M.
  • Bellevue Group's ten largest holdings make up 33% of its $1.01B portfolio in Q1 2018.
  • Bellevue Group opened 6 new positions and closed 15 in Q1 2018.
  • Bellevue Group's portfolio value rose 5.4% quarter-over-quarter to $1.01B.

Based on Bellevue Group's 13F filing for Q1 2018, filed 9 May 2018.